Ginsenoside Rh2 promotes hepatic stellate cell ferroptosis and inactivation via regulation of IRF1-inhibited SLC7A11

被引:26
|
作者
Lang, Zhichao [1 ]
Yu, Suhui [2 ]
Hu, Yuhang [1 ]
Tao, Qiqi [1 ]
Zhang, Jingnan [1 ]
Wang, Haoyue [1 ]
Zheng, Lei [1 ,3 ]
Yu, Zhixian [4 ,5 ]
Zheng, Jianjian [1 ,6 ]
机构
[1] Wenzhou Med Univ, Key Lab Clin Lab Diag & Translat Res Zhejiang Prov, Affiliated Hosp 1, Wenzhou 325000, Peoples R China
[2] Wenzhou Med Univ, Dept Hepatobiliary Surg, Affiliated Hosp 1, Wenzhou 325000, Peoples R China
[3] Southern Med Univ, Nanfang Hosp, Lab Med Ctr, Guangzhou 510515, Peoples R China
[4] Wenzhou Med Univ, Dept Urol, Affiliated Hosp 1, Wenzhou 325000, Peoples R China
[5] Wenzhou Med Univ, Dept Urol, Affiliated Hosp 1, 2 Fuxue Lane, Wenzhou, Zhejiang, Peoples R China
[6] Wenzhou Med Univ, Key Lab Clin Lab Diag & Translat Res Zhejiang Prov, Affiliated Hosp 1, 2 Fuxue Lane, Wenzhou, Zhejiang, Peoples R China
关键词
Ginsenoside Rh2; IRF1/SLC7A11 signaling pathway; Ferroptosis Hepatic stellate cells; Liver fibrosis; NANOCOMPOSITES; ALMOND;
D O I
10.1016/j.phymed.2023.154950
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Background: Sustained liver fibrosis may lead to cirrhosis. Activated hepatic stellate cells (HSCs) are crucial for liver fibrosis development. Ferroptosis, a newly iron-dependent regulated cell death, has been demonstrated to be involved in HSC inactivation. Purpose: Ginsenoside Rh2 (GRh2), a natural bioactive product derived from ginseng, has been shown to promote HSC inactivation. However, the effect of GRh2 on HSC ferroptosis remains unclear. Methods: We explored the effects of GRh2 on liver fibrosis in vivo and in vitro. RNA-sequence analysis was performed in HSCs after GRh2 treatment. The crosstalk between ferroptotic HSCs and macrophages was also explored. Results: GRh2 alleviated liver fibrosis in vivo. In vitro, GRh2 reduced HSC proliferation and activation via ferroptosis, with increased intracellular iron, reactive oxygen species, malondialdehyde and glutathione depletion. The expression of SLC7A11, a negative regulator of ferroptosis, was obviously reduced by GRh2. Interestingly, interferon regulatory factor 1 (IRF1), a transcription factor, was predicted to bind the promoter region of SCL7A11. The interaction between IRF1 and SCL7A11 was further confirmed by the results of chromatin immunoprecipitation and luciferase reporter assays. Furthermore, loss of IRF1 led to an increase in SCL7A11, which contributed to the suppression of HSC ferroptosis and the enhancement of HSC activation in GRh2-treated HSCs. Further studies revealed that GRh2-induced HSC ferroptosis contributed to the inhibition of macrophage recruitment via regulation of inflammation-related genes. Moreover, GRh2 caused a reduction in liver inflammation in vivo. Conclusion: Collectively, GRh2 up-regulates IRF1 expression, resulting in the suppression of SLC7A11, which contributes to HSC ferroptosis and inactivation. GRh2 ameliorates liver fibrosis through enhancing HSC ferroptosis and inhibiting liver inflammation. GRh2 may be a promising drug for treating liver fibrosis.
引用
收藏
页数:13
相关论文
共 38 条
  • [1] Ginsenoside Rb1 induces hepatic stellate cell ferroptosis to alleviate liver fibrosis via the BECN1/SLC7A11 axis
    Lin, Lifan
    Li, Xinmiao
    Li, Yifei
    Lang, Zhichao
    Li, Yeping
    Zheng, Jianjian
    JOURNAL OF PHARMACEUTICAL ANALYSIS, 2024, 14 (05)
  • [2] Sorafenib attenuates liver fibrosis by triggering hepatic stellate cell ferroptosis via HIF-1α/SLC7A11 pathway
    Yuan, Siyu
    Wei, Can
    Liu, Guofang
    Zhang, Lijun
    Li, Jiahao
    Li, Lingling
    Cai, Shiyi
    Fang, Ling
    CELL PROLIFERATION, 2022, 55 (01)
  • [3] Wogonoside attenuates liver fibrosis by triggering hepatic stellate cell ferroptosis through SOCS1/P53/SLC7A11 pathway
    Liu, Guofang
    Wei, Can
    Yuan, Siyu
    Zhang, Zhe
    Li, Jiahao
    Zhang, Lijun
    Wang, Guokai
    Fang, Ling
    PHYTOTHERAPY RESEARCH, 2022, 36 (11) : 4230 - 4243
  • [4] The ubiquitin hydrolase OTUB1 promotes glioma cell stemness via suppressing ferroptosis through stabilizing SLC7A11 protein
    Zhao, Xinde
    Zhou, Ming
    Yang, Yong
    Luo, Minjie
    BIOENGINEERED, 2021, 12 (02) : 12636 - 12645
  • [5] YTHDF2 Promotes Cardiac Ferroptosis via Degradation of SLC7A11 in Cardiac Ischemia-Reperfusion Injury
    Pang, Ping
    Si, Wei
    Wu, Han
    Ju, Jiaming
    Liu, Kuiwu
    Wang, Chunlei
    Jia, Yingqiong
    Diao, Hongtao
    Zeng, Linghua
    Jiang, Weitao
    Yang, Yang
    Xiong, Yuting
    Kong, Xue
    Zhang, Zhengwei
    Zhang, Feng
    Song, Jinglun
    Wang, Ning
    Yang, Baofeng
    Bian, Yu
    ANTIOXIDANTS & REDOX SIGNALING, 2024, 40 (16-18) : 889 - 905
  • [6] KCNA1 promotes the growth and invasion of glioblastoma cells through ferroptosis inhibition via upregulating SLC7A11
    Wang, Weichao
    Zhang, Yang
    Li, Xuetao
    Qinzi, E.
    Jiang, Zuoyu
    Shi, Qikun
    Huang, Yu
    Wang, Jian
    Huang, Yulun
    CANCER CELL INTERNATIONAL, 2024, 24 (01)
  • [7] KCNA1 promotes the growth and invasion of glioblastoma cells through ferroptosis inhibition via upregulating SLC7A11
    Weichao Wang
    Yang Zhang
    Xuetao Li
    Qinzi E
    Zuoyu Jiang
    Qikun Shi
    Yu Huang
    Jian Wang
    Yulun Huang
    Cancer Cell International, 24
  • [8] GAMG alleviates liver fibrosis through inducing ferroptosis in inflammatory macrophages via the IRF1/SLC7A11 signaling pathway
    Pang, Qing
    Zhou, Shuai
    Wang, Yong
    Pan, Hongtao
    Wang, Zhixin
    Qin, Xilaing
    Zhu, Chao
    Chen, Shilei
    Liu, Huichun
    Hu, Xiaosi
    Jin, Hao
    REDOX BIOLOGY, 2025, 80
  • [9] TRIM26 Induces Ferroptosis to Inhibit Hepatic Stellate Cell Activation and Mitigate Liver Fibrosis Through Mediating SLC7A11 Ubiquitination
    Zhu, Yiming
    Zhang, Chihao
    Huang, Mingzhe
    Lin, Jiayun
    Fan, Xiao
    Ni, Tao
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [10] Eupatilin mitigates ICH-induced brain injury via SOX2/SLC7A11 regulation of ferroptosis
    Shen, Youkui
    Wang, Yanqiu
    Liu, Feifei
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2025,